A new allergy medication, AllerClear, contains the exact same active compound as the leading brand, AllerSustain. However, AllerClear's unique formulation causes it to be metabolized and completely eliminated from the human body twice as rapidly as AllerSustain. Since the adverse side effects of this active compound are known to result from its presence in the bloodstream, researchers predicted that allergy sufferers would experience far fewer side effects with AllerClear. Yet, in a multi-month clinical trial where participants were instructed to take their assigned medication whenever their allergy symptoms flared up, those using AllerClear reported a significantly higher incidence of side effects than those using AllerSustain.
Which one of the following, if true, most helps to resolve the apparent discrepancy?
- AAllerSustain utilizes a specialized time-release delivery system that ensures the active compound enters the bloodstream at a gradual, steady pace rather than all at once.
- BThe specific side effects associated with the active compound typically only manifest when the chemical remains at a constant, unbroken concentration in the bloodstream for several consecutive days.
- Due to its rapid elimination, AllerClear provides only brief relief, causing participants to take the medication so frequently that their total cumulative exposure to the active compound far exceeds that of AllerSustain users.Answer
- DThe side effects associated with the active compound are generally mild, such as slight drowsiness, which most trial participants considered far less bothersome than their untreated allergy symptoms.
- EAlthough the overall incidence of side effects was higher among AllerClear users, the percentage of AllerClear users who experienced the single most severe side effect was lower than the corresponding percentage of AllerSustain users.